Jun 11, 2020
Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda to Uncover Novel Tumor-specific Regulatory T-cell Targets and Develop Unique Anti-Suppressor-Based Immunotherapies
Apr 22, 2020
CNS Pharmaceuticals to Host Shareholder Webinar Today to Discuss Coronavirus Collaboration, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin
Jan 14, 2020
CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin
Dec 09, 2019
CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event
Dec 03, 2019
CNS Pharmaceuticals to Participate in 12th Annual LD Micro Main Event Conference
Nov 26, 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Nov 04, 2019
Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting
Jul 04, 2019
Kanazawa University Research: Cancer Genes and the Tumor Milieu
Apr 02, 2019
Actym Therapeutics Will Present Data at the 2019 American Association for Cancer Research Annual Meeting
Feb 27, 2019
Silverback Therapeutics to Present Data for Lead Therapeutic Candidate SBT6050 at American Association of Cancer Research Annual Conference
Feb 05, 2019
BioInvent CSO to Present F.I.R.S.T.(TM) Discovery Platform at SLAS2019
Nov 12, 2018
Torque Presents Preclinical Data for Deep IL-15 Primed T Cells, Deep IL-12 Primed T Cells, and for the Slipstream(TM) Process for Manufacturing These First-in-Class, Multi-Target Cellular Immunotherapies
Nov 06, 2018
Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Oct 26, 2018
Lustgarten-Funded Study in Cancer Discovery Reveals Possible New Targets for Therapeutics
Oct 09, 2018
Torque Builds Out Management Team with Immunology, Clinical Development, and Manufacturing Leadership
Oct 04, 2018
Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
Jul 25, 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board